Hoffmann-La Roche Inc.

Roche Glycart Ag

Other

Roche Palo Alto LLC

F. Hoffmann-La Roche Ag

Kay-Gunnar Stubenrauch

Uwe Wessels

Rudolf Vogel

Paul Parren

Jan Van De Winkel

Yvo Graus

Martine Van Vugt

Frank Rebers

Christian Klein

Erhard Kopetzki

Beat Steiner

Anne Stern

Jacques Himber

Dorothee Kling

Miranda Jansen-Molenaar

Ulrich Essig

Frank Kowalewsky

Pamela Strein

Markus Zadak

Joerg Thomas Regula

Mirko Ritter

Ekkehard Moessner

Pablo Umana

Stefan Klostermann

Matthias Rueth

Harald Duerr

Frank Herting

Diana Darowski

Wolfgang Hoesel

Pamela Braemer

Wolfgang Schaefer

Stefan Seeber

Pablo Umaña

Peter Bruenker

Helmut Lenz

Sabine Imhof-Jung

Hubert Kettenberger

Rainer Rudolph

Ralf Schumacher

Werner Scheuer

Anita Kavlie

Adelbert Grossmann

Jigar Patel

Juergen Michael Schanzer

Monika Baehner

Josef Endl

Gregor Jordan

Roland Staack

Astrid Reiser

Jan Olaf Stracke

Sebastian Neumann

Eric Sullivan

Kevin Brady

Markus Thomas

Maria Elena Fuentes

Martin Schaefer

Rebecca Croasdale-Wood

Martina Geiger

Susanne Richter

Hauke Lilie

Sandra Vereecken-Verploegen

Joerg Thomas

Janis Brockhaus

Sylvia Rottach

Roland Beckmann

Erhard Kopetzky

Prof Van De Winkel

Maria Fuentes

Jan Stracke

The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.

Antigen binding receptors specific for mutated Fc domains

The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.

Anti-variant Fc-region antibodies and method of use

Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced by applying an inert reference antibody that does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.

Method for determining the amount of a therapeutic antibody in the brain

Herein is reported a method for the determination of the amount of a bivalent antibody in a serum or plasma sample obtained from a non-human experimental animal, whereby the antibody comprises one or more mutations in the Fc-region compared to the corresponding wild-type Fc-region that has a sequence of SEQ ID NO: 01, 02, or 03, wherein the method comprises the following steps a) immobilizing a non-antibody polypeptide to which more than one copy of the antigen of the antibody is covalently conjugated on a solid surface, b) incubating the immobilized antigen with the sample to form an immobilized antigen-antibody complex, c) incubating the immobilized antigen-antibody complex with the antigen conjugated to a detectable label to form an immobilized ternary complex, and d) determining the amount of the antibody by determining the amount of the detectable label in the immobilized ternary complex.

Immunoassay for the determination of Fc-region modified antibodies

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.

Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody

The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.

Method for determining anti-drug antibodies in a minipig sample

The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.

Protease-activated T cell bispecific molecules

The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.

Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 &#x3bc;g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.

Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.

Method for the detection of a binding partner of a multispecific binder

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of

Specific detection of rat antibodies in mouse serum

Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.

Non-cross-reactive anti IgG antibodies

Growing community of inventors

Penzberg, Germany

Kay-Gunnar Stubenrauch